Solution

About the Solution

Gene therapy employs vectors such as Adeno-Associated Virus (AAV) and lentivirus to deliver therapeutic genes into cells, but each vector has distinct integration characteristics that affect their safety and efficacy. Understanding these integration patterns is essential for optimizing therapeutic applications and ensuring patient safety. Our comprehensive guide offers strategic insights for choosing the most suitable vector, while detailing our AAV Integration Site Analysis service to assist you in making informed decisions.

At CD Genomics, we offer advanced AAV Integration Site Analysis services that elucidate the genomic integration patterns of AAV vectors. Utilizing hybrid-capture-based target enrichment sequencing (TES), our service precisely identifies and characterizes integration sites within the host genome. This analysis enhances safety evaluations by revealing potential insertional mutagenesis risks and supports the optimization of gene therapy strategies. Our comprehensive and accurate results are tailored to meet your specific research needs, ensuring that your gene therapy applications are both safe and effective.

For more information about our services, including but not limited to those listed:

• AAV (Adeno-Associated Virus) Integration Site Analysis
• Lentiviral/Retroviral Integration Sites Analysis